Abstract
Background As survival improves in patients with advanced cancer, complications such as bone marrow failure and thrombocytopenia are becoming increasingly prevalent, often limiting therapeutic options. Management becomes particularly complex when patients decline blood products, necessitating alternative strategies. Case Description We present the case of a 57-year-old male with metastatic prostate cancer to bone, complicated by progressive bone marrow failure. The patient’s decision to decline blood transfusions, consistent with his Jehovah’s Witness faith, introduced important ethical and clinical considerations. Following palliative radiotherapy for spinal cord compression, the patient developed pancytopenia, with significant thrombocytopenia (platelets 42 x109/L) and anemia (Hb 6.1 g/dL), likely due to diffuse marrow infiltration. Supportive care with erythropoietin, granulocyte colony-stimulating factor, and oral eltrombopag (a thrombopoietin receptor agonist) was initiated. Outcome Eltrombopag was well tolerated and led to a significant improvement in platelet count (to 99 x109/L), facilitating the safe reintroduction of anti-inflammatory analgesia and preventing bleeding complications without transfusion. Hemoglobin remained stable without decline. Conclusion This case highlights the utility of eltrombopag as a potentially valuable, off-label option in managing thrombocytopenia secondary to metastatic bone marrow infiltration, particularly in patients who decline transfusions. Its oral formulation, favourable safety profile, and effectiveness in improving platelet counts offer a meaningful alternative in complex palliative care scenarios. The case underscores the importance of individualised, ethically sensitive, multidisciplinary care and supports further investigation into the role of thrombopoietin receptor agonists in cancer-related bone marrow failure. References McCabe FJ, et al. (2020). The rise of metastatic bone disease in Ireland. Clinical & Experimental Metastasis. https://doi.org/10.1007/s10585-020-10059-7 Nieder C, et al. Anaemia and thrombocytopenia in patients with prostate cancer and bone metastases. BMC Cancer 2010;10, 284. https://doi.org/10.1186/1471-2407-10-284 Winer ES, Safran H, Karaszewska B, Bauer S, Khan D, Doerfel S, Burgess P, Kalambakas S, Mostafa Kamel Y, Forget F. Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: a randomized, placebo-controlled phase 2 study. International Journal of Hematology 2017;106(6). https://doi.org/10.1007/s12185-017-2319-9 Chen W, Liu Y, Li L, Zeng X. Efficacy and safety of thrombopoietin receptor agonists in solid tumors with chemotherapy-induced thrombocytopenia: a meta-analysis. In BMC Pharmacology and Toxicology 2023;24(1). https://doi.org/10.1186/s40360-023-00707-5 Kuter DJ. (2015). Managing thrombocytopenia associated with cancer chemotherapy. In Oncology (Williston Park, N.Y.) (Vol. 29, Issue 4. National Cancer Registry Ireland, 2019. Cancer incidence projections for Ireland 2020-2045. Cancer incidence projections for Ireland 2020–2045.